1.
Clinical characteristics of patients in the two groups
| Characteristics | CIK group | Control group | P |
| Patients, n | 147 | 147 | |
| Age (years) | 1.000 | ||
| < 35 | 9 | 9 | |
| ≥ 35 | 138 | 138 | |
| Tumor size (cm) | 0.644 | ||
| ≤ 2 | 64 | 68 | |
| > 2, ≤ 5 | 65 | 58 | |
| > 5 | 11 | 14 | |
| Unable to value | 7 | 7 | |
| Lymph node metastasis | 0.338 | ||
| Yes | 53 | 61 | |
| No | 94 | 86 | |
| TNM stage | 0.064 | ||
| I | 46 | 43 | |
| IIa | 56 | 56 | |
| IIb | 23 | 11 | |
| IIIa | 5 | 14 | |
| IIIb | 1 | 2 | |
| IIIc | 9 | 15 | |
| Unable to value | 7 | 6 | |
| Histological grade | 0.365 | ||
| 1 | 0 | 2 | |
| 2 | 89 | 88 | |
| 3 | 58 | 57 | |
| Pathological type | 0.069 | ||
| Invasive ductal carcinoma | 138 | 129 | |
| Others | 9 | 18 | |
| Surgery | 0.469 | ||
| Radical mastectomy | 24 | 17 | |
| Modified radical mastectomy | 110 | 118 | |
| Breast-conserving surgery | 13 | 12 | |
| Radiotherapy | 0.162 | ||
| Yes | 38 | 28 | |
| No | 109 | 119 | |
| Neoadjuvant chemotherapy | 1.000 | ||
| Yes | 21 | 21 | |
| No | 126 | 126 | |
| Adjuvant chemotherapy regimens | 0.319 | ||
| Anthracycline-based | 17 | 10 | |
| Anthracycline-and taxane-based | 113 | 122 | |
| Taxane-based | 17 | 15 |